SNBC and SINERGY Event – Microbiome & Gut Health: Current Perspective and Applications, 12 August 2021
Date and time: 12 August 2021, 3-4pm (GMT+8)
Who should attend?
Companies, investors, academics and regulators interested in gut health
• Welcome address – SNBC & SINERGY
• Current perspectives from session moderator and panel members (20 mins)
• Q&A and Discussion (30 mins)
Panel Discussion Speakers: Singapore National Biofilm Consortium (SNBC) & SINERGY
Patricia Conway (Session Moderator)
Dr Patricia Conway is a Visiting Professor at the School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore and Adjunct Prof at UNSW Australia. Her research interests are gastrointestinal microbiology, probiotics and prebiotics with particular emphasis on bacterial colonization and function within the gastrointestinal tract. She has been working to combine basic research and translational applications for over 30 years working closely with industry and academics in the field.
Dr Joachim Loo is Associate Professor in the School of Materials Science and Engineering (MSE) at the Nanyang Technological University (NTU). He holds joint appointments at the SCELSE (www.scelse.sg), the Lee Kong Chian School of Medicine (NTU), and is also a Visiting Scientist at the Harvard School of Public Health (HSPH), USA. His research interests include designing Joachim Loo encapsulation /delivery systems for agri-food and biomedical applications. Recently, he spun-off two companies, i.e. LiberaTx and Dietrics, to develop oral formulations for therapeutics and as a food ingredient respectively. He is also co-convenor of the ISO/TC 229 Nanotechnology National Working Group (WG3), under the Singapore Chemical Industry Council.
Dr Michael Patane is Head of Innovation and Technical APAC for DSM Human Nutrition and Health. His research interests include the extraction and encapsulation of bioactive molecules for controlled delivery and release for the improvement of general and microbiome health. Michael has been working in the food and Pharma fields for 40 years and has developed multiple patented technologies.
In Young Hwang
In Young Hwang is a Research Assistant Professor at the Department of Biochemistry, Yong Loo Lin School of Medicine, NUS, and a Principal Investigator, NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI). In Young has received her Ph.D in the field of cancer biology and therapeutics from University of Auckland. Since then, she has expanded her research interest to Synthetic Biology by joining the Chang lab in 2012. She has made contributions in enabling various programmable functionalities in microbes to execute the pathogen detection-mediated pathogen killing activity. Her research was published in ACS synthetic biology and Nature Communications, as well as being notably mentioned in various media including Nature and The Economist. She serves as a reviewer for international journals such as Biotechnology journal, Chemical Engineering Science and 3Biotech. Her current research focuses on in-depth study and modulation of the gut microbiome and its various physiological axis for human health and therapy.
Dr Jonathan Lee serves on AMILI’s Board of Advisors. He is a Consultant specialising in Gastroenterology and Hepatology at the National University Hospital, Singapore. Dr Lee completed his postgraduate residency training in NUH, a fellowship training in Gastroenterology and Hepatology, and was certified by the Specialist Jonathan Lee Accreditation Board of Singapore in 2017. Dr Lee has a keen interest in endoscopic screening and treatment of gastrointestinal cancers. Dr Lee’s research interest is in the role of the microbiome associated with gastrointestinal diseases, and is actively involved as principal investigator in basic and translational research on this subject.